These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36125712)

  • 41. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
    Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
    Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver.
    Kim M; Jeong M; Hur S; Cho Y; Park J; Jung H; Seo Y; Woo HA; Nam KT; Lee K; Lee H
    Sci Adv; 2021 Feb; 7(9):. PubMed ID: 33637537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cuboplexes: Topologically Active siRNA Delivery.
    Kim H; Leal C
    ACS Nano; 2015 Oct; 9(10):10214-26. PubMed ID: 26390340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doping hydroxylated cationic lipid into PEGylated cerasome boosts in vivo siRNA transfection efficacy.
    Li Y; Zheng S; Liang X; Jin Y; Wu Y; Bai H; Liu R; Dai Z; Liang Z; Shi T
    Bioconjug Chem; 2014 Nov; 25(11):2055-66. PubMed ID: 25260060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.
    Hsu SH; Yu B; Wang X; Lu Y; Schmidt CR; Lee RJ; Lee LJ; Jacob ST; Ghoshal K
    Nanomedicine; 2013 Nov; 9(8):1169-80. PubMed ID: 23727126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology.
    An K; Kurek D; Mahadeo M; Zhang Y; Thewalt JL; Cullis PR; Kulkarni JA
    Langmuir; 2022 Nov; 38(46):14036-14043. PubMed ID: 36367350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations.
    Wang X; Yu B; Ren W; Mo X; Zhou C; He H; Jia H; Wang L; Jacob ST; Lee RJ; Ghoshal K; Lee LJ
    J Control Release; 2013 Dec; 172(3):690-8. PubMed ID: 24121065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells.
    Liu GW; Guzman EB; Menon N; Langer RS
    Pharm Res; 2023 Jan; 40(1):3-25. PubMed ID: 36735106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery.
    Steffens RC; Wagner E
    Pharm Res; 2023 Jan; 40(1):47-76. PubMed ID: 36109461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tuning the Immunostimulation Properties of Cationic Lipid Nanocarriers for Nucleic Acid Delivery.
    Dey AK; Nougarède A; Clément F; Fournier C; Jouvin-Marche E; Escudé M; Jary D; Navarro FP; Marche PN
    Front Immunol; 2021; 12():722411. PubMed ID: 34497612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO Liposomal System.
    Oliveira ACN; Fernandes J; Gonçalves A; Gomes AC; Oliveira MECDR
    Curr Drug Targets; 2019; 20(1):29-50. PubMed ID: 29968536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
    Kulkarni JA; Darjuan MM; Mercer JE; Chen S; van der Meel R; Thewalt JL; Tam YYC; Cullis PR
    ACS Nano; 2018 May; 12(5):4787-4795. PubMed ID: 29614232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
    Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L
    Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?
    Berger M; Lechanteur A; Evrard B; Piel G
    Int J Pharm; 2021 Aug; 605():120851. PubMed ID: 34217823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
    Foca A; Dhillon A; Lahlali T; Lucifora J; Salvetti A; Rivoire M; Lee A; Durantel D
    Antivir Ther; 2020; 25(3):151-162. PubMed ID: 32496211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of vitronectin-rich protein corona on tumor-specific siRNA delivery and transfection with lipid nanoparticles.
    Chen D; Ganesh S; Wang W; Lupieri A; Amiji M
    Nanomedicine (Lond); 2021 Mar; 16(7):535-551. PubMed ID: 33683145
    [No Abstract]   [Full Text] [Related]  

  • 57. Nonendocytic delivery of lipoplex nanoparticles into living cells using nanochannel electroporation.
    Boukany PE; Wu Y; Zhao X; Kwak KJ; Glazer PJ; Leong K; Lee LJ
    Adv Healthc Mater; 2014 May; 3(5):682-9. PubMed ID: 23996973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Universal Barcoding Predicts
    Da Silva Sanchez AJ; Dobrowolski C; Cristian A; Echeverri ES; Zhao K; Hatit MZC; Loughrey D; Paunovska K; Dahlman JE
    Nano Lett; 2022 Jun; 22(12):4822-4830. PubMed ID: 35671473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis of lipidic magnetic nanoparticles for nucleic acid delivery.
    Namiki Y
    Methods Mol Biol; 2013; 948():243-50. PubMed ID: 23070774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides.
    del Pozo-Rodríguez A; Delgado D; Solinís MA; Gascón AR
    Recent Pat Drug Deliv Formul; 2011 Sep; 5(3):214-26. PubMed ID: 21834776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.